NurExone Biologic Extends Spinal Cord Injury Therapy Portfolio With New RNA Sequences Promoting Healing and Regeneration
29 nov. 2023 08h30 HE
|
NurExone Biologic Inc
NurExone Biologic expands its portfolio of products to address spinal cord injuries & neuron regeneration in CNS indications
NurExone Reports Third Quarter 2023 Financial Results and Provides Corporate Update
24 nov. 2023 08h30 HE
|
NurExone Biologic Inc
NurExone released a corporate update and reported financial results for the quarter ended September 30, 2023.
NurExone Biologic Receives FDA Orphan-Drug Designation, Accelerating Development of ExoPTEN therapy for Acute Spinal Cord Injury Treatment
30 oct. 2023 09h20 HE
|
NurExone Biologic Inc
NurExone Biologic Receive FDA Orphan-Drug Designation to its ExoPTEN Therapy for Acute Spinal Cord Injury Treatment
Appointment of Professor Teo Forcht Dagi to Scientific Advisory Board and Advisory Committee
19 oct. 2023 08h30 HE
|
NurExone Biologic Inc
NurExone Biologic welcomes Prof. Teodoro Forcht Dagi, a renowned neurosurgeon and life science venture capitalist, to its Scientific Advisory Board.
NurExone Secures Eureka Grant for Collaborative Partnership to Expand to Chronic Spinal Cord Injury Therapy
11 oct. 2023 08h30 HE
|
NurExone Biologic Inc
NurExone has been awarded a grant by the Israel Innovation Authority (“IIA”) as part of the Israel-Canada bilateral Eureka program
NurExone Biologic to Present Exosome-Based Therapy for Spinal Cord Injury in Regenerative Medicine Session at Upcoming Extracellular Vesicles Forum
05 oct. 2023 08h30 HE
|
NurExone Biologic Inc
NurExone Biologic will present at the EVs Forum in Cambridge presents advances in exosome therapy for spinal cord injuries, highlighting ExoPTEN potential
NurExone Appoints Dr. Reuter Investor Relations in Europe
28 sept. 2023 08h30 HE
|
NurExone Biologic Inc
NurExone partners with Dr. Reuter Investor Relations for European investor relations services. TSX approves NurExone's warrant amendments.
NurExone Moves Forward Towards Human Clinical Trials, Completes Pre-IND Meeting with the FDA for Proprietary ExoPTEN Drug
13 sept. 2023 08h30 HE
|
NurExone Biologic Inc
The FDA’s response indicated that the planned toxicity study strategy is acceptable under FDA guidelines and large-scale animal studies will not be required. The completed Pre-IND meeting with the...
NurExone Announces Closing of Second Tranche of Private Placement, bringing total raise at this round to approximately CAD$1.5M
06 sept. 2023 08h30 HE
|
NurExone Biologic Inc
TORONTO and HAIFA, Israel, Sept. 06, 2023 (GLOBE NEWSWIRE) -- NurExone Biologic Inc. (TSXV: NRX) (FSE: J90) (NRX.V) (the “Company” or “NurExone”), a biopharmaceutical company developing...
NurExone Reports Second Quarter 2023 Financial Results and Provides Corporate Update
28 août 2023 08h30 HE
|
NurExone Biologic Inc
Completed the first tranche of a non-brokered private placement offering of units for gross proceeds of approximately CAD$1.3 million to extend cash runway into 2024Strengthened the Board of Directors...